ALAN H. AUERBACH - 07 Feb 2025 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
Issuer symbol
PBYI
Transactions as of
07 Feb 2025
Net transactions value
$0
Form type
4
Filing time
11 Feb 2025, 18:51:06 UTC
Previous filing
03 Jan 2025
Next filing
10 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Award $0 +198,399 +2.8% $0.000000 7,228,073 07 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBYI Stock Option (Right to Buy) Award $0 +274,622 $0.000000 274,622 07 Feb 2025 Common Stock 274,622 $2.78 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events.
F2 Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events.